Abstract

The prediction of primary treatment failure (PTF) is necessary for patients with diffuse large B-cell lymphoma (DLBCL) since it serves as a prominent means for improving front-line outcomes. Using interim 18F-fluoro-2-deoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) imaging data, we aimed to construct multimodal deep learning (MDL) models to predict possible PTF in low-risk DLBCL. Initially, 205 DLBCL patients undergoing interim [18F]FDG PET/CT scans and the front-line standard of care were included in the primary dataset for model development. Then, 44 other patients were included in the external dataset for generalization evaluation. Based on the powerful backbone of the Conv-LSTM network, we incorporated five different multimodal fusion strategies (pixel intermixing, separate channel, separate branch, quantitative weighting, and hybrid learning) to make full use of PET/CT features and built five corresponding MDL models. Moreover, we found the best model, that is, the hybrid learning model, and optimized it by integrating the contrastive training objective to further improve its prediction performance. The final model with contrastive objective optimization, named the contrastive hybrid learning model, performed best, with an accuracy of 91.22% and an area under the receiver operating characteristic curve (AUC) of 0.926, in the primary dataset. In the external dataset, its accuracy and AUC remained at 88.64% and 0.925, respectively, indicating its good generalization ability. The proposed model achieved good performance, validated the predictive value of interim PET/CT, and holds promise for directing individualized clinical treatment. • The proposed multimodal models achieved accurate prediction of primary treatment failure in DLBCL patients. • Using an appropriate feature-level fusion strategy can make the same class close to each other regardless of the modal heterogeneity of the data source domain and positively impact the prediction performance. • Deep learning validated the predictive value of interim PET/CT in a way that exceeded human capabilities.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.